Overexpression of MiR-29b-3p Inhibits Atrial Remodeling in Rats by Targeting PDGF-B Signaling Pathway

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2021 Feb 1

PMID 33520084

Citations 8

Authors

Xiangwei Lv

Pan Lu

Yisen Hu

Tongtong Xu

Affiliations

Soon will be listed here.

Abstract

Purpose: Studies have found that microRNAs (miRNAs) are closely associated with atrial fibrillation, but their specific mechanism remains unclear. The purpose of this experiment is to explore the function of miR-29b-3p in regulating atrial remodeling by targeting PDGF-B signaling pathway and thereby also explore the potential mechanisms.

Methods: We randomly divided twenty-four rats into four groups. Caudal intravenous injections of angiotensin-II (Ang-II) were administered to establish atrial fibrosis models. Expressions of miR-29b-3p and PDGF-B were then tested via RT-PCR, western blot, and immunohistochemistry. Binding sites were then analyzed via the bioinformatics online software TargetScan and verified by Luciferase Reporter. We used Masson staining to detect the degree of atrial fibrosis, while immunofluorescence and western blot were used to detect the expressions of Collagen-I and a-SMA. We used immunohistochemistry and western blot to detect the expression of connexin 43 (Cx43).

Results: In comparison with the Ang-II group, miR-29b-3p was seen to lower the degree of atrial fibrosis, decrease the expression of fibrosis markers such as Collagen-I and a-SMA, and increase the protein expression of Cx43. MiR-29b-3p can lower the expression of PDGF-B, while the Luciferase Reporter showed that PDGF-B is the verified target gene of miR-29b-3p.

Conclusions: MiR-29b-3p was able to reduce atrial structural and electrical remodeling in the study's rat fibrosis model. This biological function may be expressed through the targeted regulation of the PDGF-B signaling pathway.

Citing Articles

MicroRNAs in atrial fibrillation - have we discovered the Holy Grail or opened a Pandora's box?.

Balan A, Scridon A Front Pharmacol. 2025; 16:1535621.

PMID: 40012622 PMC: 11861496. DOI: 10.3389/fphar.2025.1535621.

Perspective and Therapeutic Potential of the Noncoding RNA-Connexin Axis.

Li X, Wang Z, Chen N Int J Mol Sci. 2024; 25(11).

PMID: 38892334 PMC: 11173347. DOI: 10.3390/ijms25116146.

Predictive Value of Serum microRNA-29b-3p in Recurrence of Atrial Fibrillation After Radiofrequency Catheter Ablation.

Zhan J, Peng C, Liu Y, Bi Z, Lu G, Hao S Clin Interv Aging. 2024; 19:715-725.

PMID: 38716143 PMC: 11075679. DOI: 10.2147/CIA.S450292.

Non-Coding Ribonucleic Acids as Diagnostic and Therapeutic Targets in Cardiac Fibrosis.

Olson S, Tang W, Liu C Curr Heart Fail Rep. 2024; 21(3):262-275.

PMID: 38485860 PMC: 11090942. DOI: 10.1007/s11897-024-00653-1.

Research progress of non-coding RNA in atrial fibrillation.

Xue Z, Zhu J, Liu J, Wang L, Ding J Front Cardiovasc Med. 2023; 10:1210762.

PMID: 37522088 PMC: 10379658. DOI: 10.3389/fcvm.2023.1210762.

References

Heijman J, Voigt N, Nattel S, Dobrev D . Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014; 114(9):1483-99. DOI: 10.1161/CIRCRESAHA.114.302226. View

Zhang Y, Huang X, Wei L, Chung A, Yu C, Lan H . miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. Mol Ther. 2014; 22(5):974-85. PMC: 4015231. DOI: 10.1038/mt.2014.25. View

He X, Zhang K, Gao X, Li L, Tan H, Chen J . Rapid atrial pacing induces myocardial fibrosis by down-regulating Smad7 via microRNA-21 in rabbit. Heart Vessels. 2016; 31(10):1696-708. PMC: 5043001. DOI: 10.1007/s00380-016-0808-z. View

Razmi N, Baradaran B, Hejazi M, Hasanzadeh M, Mosafer J, Mokhtarzadeh A . Recent advances on aptamer-based biosensors to detection of platelet-derived growth factor. Biosens Bioelectron. 2018; 113:58-71. DOI: 10.1016/j.bios.2018.04.048. View

Chinitz J, Castellano J, Kovacic J, Fuster V . Atrial fibrillation, stroke, and quality of life. Ann N Y Acad Sci. 2012; 1254:140-150. DOI: 10.1111/j.1749-6632.2012.06494.x. View

Donovan J, Abraham D, Norman J . Platelet-derived growth factor signaling in mesenchymal cells. Front Biosci (Landmark Ed). 2013; 18(1):106-19. DOI: 10.2741/4090. View

Greiser M, Schotten U . Dynamic remodeling of intracellular Ca²⁺ signaling during atrial fibrillation. J Mol Cell Cardiol. 2013; 58:134-42. DOI: 10.1016/j.yjmcc.2012.12.020. View

Ling T, Wang X, Chai Q, Lau T, Koestler C, Park S . Regulation of the SK3 channel by microRNA-499--potential role in atrial fibrillation. Heart Rhythm. 2013; 10(7):1001-9. PMC: 3710704. DOI: 10.1016/j.hrthm.2013.03.005. View

Sassi Y, Avramopoulos P, Ramanujam D, Gruter L, Werfel S, Giosele S . Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun. 2017; 8(1):1614. PMC: 5696364. DOI: 10.1038/s41467-017-01737-4. View

10.

Goudis C, Kallergis E, Vardas P . Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace. 2012; 14(5):623-30. DOI: 10.1093/europace/eur398. View

11.

Jiang Z, Zhong G, Wen L, Hong Y, Fang S, Sun P . The Role of Platelet-Derived Growth Factor-B/Platelet-Derived Growth Factor Receptor-β Signaling in Chronic Atrial Fibrillation. Cardiology. 2016; 133(4):242-56. DOI: 10.1159/000442940. View

12.

Shen W, Li L, Song B, Li W, Zhou Z, Guo R . Platelet-derived growth factor-BB increases expression of connexin 43 in an extracellular-regulated protein kinase-dependent manner in bladder smooth muscle cells. Int J Urol. 2012; 20(1):123-30. DOI: 10.1111/j.1442-2042.2012.03192.x. View

13.

Duffy H . The ever-shrinking world of cardiac ion channel remodeling: the role of microRNAs in heart disease. Heart Rhythm. 2009; 6(12):1810-1. PMC: 2831611. DOI: 10.1016/j.hrthm.2009.09.021. View

14.

Tuuminen R, Dashkevich A, Keranen M, Raissadati A, Krebs R, Jokinen J . Platelet-derived Growth Factor-B Protects Rat Cardiac Allografts From Ischemia-reperfusion Injury. Transplantation. 2015; 100(2):303-13. DOI: 10.1097/TP.0000000000000909. View

15.

Weckbach L, Grabmaier U, Clauss S, Wakili R . MicroRNAs as a diagnostic tool for heart failure and atrial fibrillation. Curr Opin Pharmacol. 2016; 27:24-30. DOI: 10.1016/j.coph.2016.01.001. View

16.

Awada H, Johnson N, Wang Y . Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction. J Control Release. 2015; 207:7-17. PMC: 4430430. DOI: 10.1016/j.jconrel.2015.03.034. View

17.

Wang J, Wang Y, Han J, Li Y, Xie C, Xie L . Integrated analysis of microRNA and mRNA expression profiles in the left atrium of patients with nonvalvular paroxysmal atrial fibrillation: Role of miR-146b-5p in atrial fibrosis. Heart Rhythm. 2015; 12(5):1018-26. DOI: 10.1016/j.hrthm.2015.01.026. View

18.

Clauss S, Sinner M, Kaab S, Wakili R . The Role of MicroRNAs in Antiarrhythmic Therapy for Atrial Fibrillation. Arrhythm Electrophysiol Rev. 2016; 4(3):146-55. PMC: 4732177. DOI: 10.15420/aer.2015.4.3.146. View

19.

Igarashi T, Finet J, Takeuchi A, Fujino Y, Strom M, Greener I . Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2011; 125(2):216-25. PMC: 3260348. DOI: 10.1161/CIRCULATIONAHA.111.053272. View

20.

Miyasaka Y, Barnes M, Gersh B, Cha S, Bailey K, Abhayaratna W . Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114(2):119-25. DOI: 10.1161/CIRCULATIONAHA.105.595140. View